Karyopharm Grants 1,450 RSUs to New Hires

Equity awards will vest over three years for two new Karyopharm employees.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, announced that it has granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees. The RSU awards were granted on February 28, 2026 pursuant to the company's 2022 Inducement Stock Incentive Plan, as inducements material to the new employees entering into employment with Karyopharm.

Why it matters

The RSU grants are part of Karyopharm's efforts to attract and retain top talent as it continues to develop novel cancer therapies. Inducement grants like these are common in the pharmaceutical industry to incentivize new hires.

The details

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm.

  • The RSU awards were granted on February 28, 2026.

The players

Karyopharm Therapeutics Inc.

A commercial-stage pharmaceutical company pioneering novel cancer therapies.

Got photos? Submit your photos here. ›

The takeaway

The RSU grants demonstrate Karyopharm's commitment to building a strong team as it continues to advance its pipeline of cancer therapies. Inducement grants like these are a common tool used by pharmaceutical companies to attract top talent in a competitive job market.